Cite
HARVARD Citation
Gelmon, K. et al. (2021). Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. European journal of cancer. pp. 68-77. [Online].